SUNNYVALE, Calif., May 11, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2022 and filed its quarterly report on Form 10-Q for the three months ended March 31, […]
Financial
Liquidia Reports First Quarter 2022 Financial Results and Provides Corporate Update
– Secured access to new capital through debt and equity transactions – Increased utilization of Treprostinil Injection with increasing payer generic mandates – Advanced Hatch-Waxman litigation in support of final regulatory approval of YUTREPIA™ (treprostinil) inhalation powder – Company to host webcast and conference call today at 8:30 a.m. ET […]
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM ongoing LianBio’s partner, Tarsus, announced positive topline data from the Phase 3 Saturn-2 clinical trial […]
Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
TN-201 Received Orphan Medicinal Product Designation from the European Commission Preclinical TN-401 Data Presented at Heart Rhythm 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today […]
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022. “We remain focused on […]
Acarix AB (publ) publishes Interim Report, January – March 2022
Increased commercial momentum and great interest in CADScor® System on the US market 2022 has started off positiv with important steps on the US market, recruitment of key staff and continued validation that our business model works. We report doubled sales of patches compared with the corresponding quarter of 2021. […]
Tridentcare Partners With Harness Health Partners for Digital Imaging and Electrocardiogram (EKG) Nationwide
SPARKS, Md., May 10, 2022 (GLOBE NEWSWIRE) — TridentCare, a national leader of portable diagnostic services, announces its new partnership with Harness Health Partners to provide mobile X-ray, Ultrasound and EKG services across the United States. “This is an exciting time for TridentCare,” says TridentCare CEO David Velez. “We are excited […]
BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements
Westport, CT, May 11, 2022 (GLOBE NEWSWIRE) — To date, Company’s FDA 510(k) cleared PURE EP(TM) system has completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States The Company adds new executives to accelerate sustained commercial momentum developing a national installed base of the PURE EP […]
CARMAT Announces the Approval of All Resolutions Supported by the Board of Directors at Its Annual General Meeting
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, informs its shareholders that the annual general meeting (AGM) of May 11, […]
Shockwave Medical Reports First Quarter 2022 Financial Results
SANTA CLARA, Calif., May 09, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2022. Recent Highlights Recognized revenue of $93.6 million […]
Recent
New Study Highlights Safety and Efficacy Profile of Haemonetics’ VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
Guerbet announces an important milestone achievement in the “Vascular Embolization” indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil)
Reflow Medical Announces U.S. Launch of Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters
Popular
- No commented posts yet